Observational study of fruquintinib in metastatic colorectal cancer patients
Studies how patients with metastatic colorectal cancer do on fruquintinib in routine care.
Plain-language title generated from the registry record
Registry title: Fruquintinib in Patients With Metastatic Colorectal Cancer
Key facts
- Where
- Aschaffenburg, Berlin, Biberach, Cologne, Cottbus, Dresden, Essen, Frechen, Freiburg im Breisgau, Fürth, Goslar, Hamburg, Hanover, Heidelberg, Hof, Idar-Oberstein, Landshut, Lebach, Leer, München, Naunhof, Neustadt am Rübenberge, Potsdam, Ratingen, Ravensburg, Regensburg, Rosenheim, Schorndorf, Soest, Speyer, Stolberg, Ulm, Weinheim, Wermelskirchen, Wilhelmshaven, and Zittau, GermanySee the 42 sites
Where in Germany
- MVZ am Klinikum Aschaffenburg GmbHAschaffenburg, GermanyTaking people
- DRK Kliniken Berlin Köpenick Klinik für Allgemein-, Viszeral- & Minimalinvasive ChirurgieBerlin, GermanyTaking people
- Evangelisches Waldkrankenhaus Spandau Innere Medizin IBerlin, GermanyTaking people
- Hämatologikum BiberachBiberach, GermanyTaking people
- MVZ für Hämatologie und Onkologie Köln Am Sachsenring GmbHCologne, GermanyTaking people
- Ambulantes Zentrum für Hämatologie & OnkologieCottbus, GermanyTaking people
- BAG / Onkologische GemeinschaftspraxisDresden, GermanyTaking people
- Gemeinschaftspraxis Dr. Mohm / Dr. Siklaky / MannDresden, GermanyTaking people
- Onkozentrum DresdenDresden, GermanyTaking people
- Evang. Kliniken Essen-Mitte (KEM) Internistische OnkologieEssen, GermanyTaking people
- Praxis Internistischer Onkologie und Hämatologie (PIOH)Frechen, GermanyTaking people
- Praxis für interdisziplinäre Onkologie & HämatologieFreiburg im Breisgau, GermanyTaking people
- Schwerpunktpraxis Hämatologie & Internistische OnkologieFürth, GermanyTaking people
- ÜBAG Onkologische Kooperation Harz GbRGoslar, GermanyTaking people
- Hämatologisch Onkologische Praxis Eppendorf (HOPE)Hamburg, GermanyTaking people
- Überörtliche Gemeinschaftspraxis Schwerpunkt Haematologie, internist Onkologie & PalliativmedizinHamburg, GermanyTaking people
- Gemeinschaftspraxis Dr. Haytham Kamal und Dr. David C. DornHanover, GermanyTaking people
- Onkologische SchwerpunktpraxisHanover, GermanyTaking people
- Onkologische SchwerpunktpraxisHeidelberg, GermanyTaking people
- Onkologie Hof MVZ GmbHHof, GermanyTaking people
- SHG Klinikum Idar-Oberstein Med. Klinik I: Gastroenterologie, Nephrologie, Hämatologie, OnkologieIdar-Oberstein, GermanyTaking people
- Dr. Vehling-Kaiser MVZ GmbH LandshutLandshut, GermanyTaking people
- Gemeinschaftspraxis für Hämatologie und Onkologie GbRLebach, GermanyTaking people
- Onkologie UnterEms Leer-Emden-Papenburg Dr. L. MüllerLeer, GermanyTaking people
- Hämatologie und Onkologie München-Pasing MVZ GmbHMünchen, GermanyTaking people
- Praxis Dr. MichlMünchen, GermanyTaking people
- Praxis Dr. med. Jens UhligNaunhof, GermanyTaking people
- MVZ Onko Medical GmbHNeustadt am Rübenberge, GermanyTaking people
- BAG Onkologie am FilmparkPotsdam, GermanyTaking people
- Praxis für Hämatologie und internistische OnkologieRatingen, GermanyTaking people
- MVZ für Hämatologie und Onkologie Ravensburg GmbH - StudienzentrumRavensburg, GermanyTaking people
- Schwerpunktpraxis und Tagesklinik für Hämatologie und OnkologieRegensburg, GermanyTaking people
- Klinikum Rosenheim Medizinische Klinik IIRosenheim, GermanyTaking people
- Zentrum Ambulante OnkologieSchorndorf, GermanyTaking people
- MVZ Kloster Paradiese GbR Schwerpunktpraxis für Hämatologie u OnkologieSoest, GermanyTaking people
- Onkologische Schwerpunktpraxis SpeyerSpeyer, GermanyTaking people
- Hämatologie - Onkologie - StolbergStolberg, GermanyTaking people
- Universitätsklinikum Ulm Klinik für Innere Medizin I Gastroenterologie, NephrologieUlm, GermanyTaking people
- ze:ro Praxen MVZ für Innere Medizin WeinheimWeinheim, GermanyTaking people
- KHOP - Kalkan Hämatologie Onkologie PalliativmedizinWermelskirchen, GermanyTaking people
- MVZ für Onkologie und Urologie GmbHWilhelmshaven, GermanyTaking people
- Praxis und Tagesklinik für Hämatologie/OnkologieZittau, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT06787105
- Record updated
- 4 September 2026
- Original description
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies.Read full original descriptionShow less
Fruquintinib in Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter, Observational Study
FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies.
To this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib.
Participants will be treated as decided by the treating physician and according to their routine practice.
FRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.
Inclusion: Aged 18 years or older; Indication and decision for therapy with fruquintinib in accordance with the current German SmPC of fruquintinib as monotherapy for patients with mCRC; Prior treatment with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF therapy, and if RAS wild-type, anti EGFR therapy; Progression on or intolerance to treatment with either trifluridine/tipiracil and/or regorafenib; Other criteria according to current SmPC; Signed written informed consent.* * Patients are allowed to be enrolled up to 6 weeks after their first dose of fruquintinib. These patients cannot participate in the PRO assessments.
Exclusion: Participation in an interventional clinical trial (except follow-up) within 30 days prior to enrollment or start of treatment with fruquintinib, whatever comes first; Contraindications according to current SmPC.